



# Supplementary Materials: Uremic Apelin and Leucocytic Angiotensin-Converting Enzyme 2 in CKD Patients

Bogusz Trojanowicz, Christof Ulrich and Matthias Girndt



**Figure S1.** Expression of (A) leucocytic MAS receptor (MASR) and its correlation with (B) leucocytic APLNR. Correlation between serum APLN and (C) AT1R, (D) AT2R and (E) MASR; fold difference values were calculated by comparison to expression of the target transcript in the reference sample and for the evaluation purposes was set as 1; medians with IRQs; p values \* < 0.01, \*\*<0.001 and \*\*\*<0.0001 indicate statistical significance (Bonferroni correction was applied).



**Figure S2.** Serum (A) APLN and (B) Ang1-7 and (C) leucocytic expression of APLNR in CKD patients treated with AngII receptor blocker (ARB+) or Angiotensin Converting Enzyme Inhibitor (ACEi+); levels of serum Ang1-7 were measured as mentioned previously [27]. (D) Serum APLN in healthy controls (NP), HD and not-dialysed CKD3-5 patients; fold difference values were calculated by comparison to expression of the target transcript in the reference sample and for the evaluation purposes was set as 1; medians with IRQs; p values \*<0.01, \*\*<0.001 and \*\*\*<0.0001 indicate statistical significance (Bonferroni correction was applied).